Early-onset IBM challenges age-centric diagnostic criteria, with symptoms appearing in patients younger than 46. Younger IBM patients show a higher rate of mitochondrial DNA mutations, indicating ...
LOS ANGELES, Feb. 11, 2020 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, ...
NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T ...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases has awarded UCI a 5-year, $4.2 million grant to study sporadic inclusion body myositis (sIBM), which affects aging adults ...
NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T ...
Irvine, CA - April 6, 2021 - The National Institute of Arthritis and Musculoskeletal and Skin Diseases has awarded UCI a 5-year, $4.2 million grant to study sporadic inclusion body myositis (sIBM), ...
Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Many patients who might have previously been diagnosed with polymyositis are now being treated for ...
Frampton highlights how it's "humbling" to feel fans' "special love for me when I do a concert" Myrna M. Suarez/Getty Images Peter Frampton hopes fans "appreciate the fact that I’m not giving up." The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback